<DOC>
	<DOCNO>NCT01505062</DOCNO>
	<brief_summary>To evaluate safety tolerability ascend dos subretinal injection UshStat patient Usher syndrome type 1B . To evaluate possible biological activity UshStat .</brief_summary>
	<brief_title>Study UshStat Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B</brief_title>
	<detailed_description>Following screening procedure gene transfer agent inject one retina opthalmic surgeon anesthesia . Patients regular follow visit general health examination , blood test ophthalmic examination include best correct visual acuity , slit lamp examination , intraocular pressure , fundoscopy , autofluorescence , Optical Coherence Tomography , perimetry Electroretinogram undertaken . At end study , patient invite enter open-label safety study long-term follow-up visit ( least every six month ) include ophthalmological examination record adverse event continue 5 year ; Investigator follow patient subsequent 10 year minimum interval year monitor delay adverse event .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Retinitis Pigmentosa</mesh_term>
	<mesh_term>Usher Syndromes</mesh_term>
	<criteria>Clinical molecular diagnosis Retinitis Pigmentosa associate Usher Syndrome type 1B . With least one pathogenic mutation MYO7A gene chromosome . Suitable verbal , auditory , write and/or tactile sign language communication allow informed consent obtain . Women childbearing potential must agree use two form contraception . Males must agree use two form contraception study partner childbearing potential three month treatment . Presence significant ocular abnormality would preclude surgery , effective study follow interfere study endpoint . Concomitant systemic disease alter visual function . Contraindication pupil dilation , anesthesia eye surgery . Periocular steroids last four month prior screen . Known allergy component delivery vehicle diagnostic agent dilation drop . Lifethreatening illness history malignancy within 5 year Laboratory test abnormality would make patient unsuitable participation study Intercurrent illnesses infection 28 day prior treatment Concurrent antiretroviral immunosuppressant therapy Men woman agree use contraception specify inclusion criterion . Pregnant breastfeed woman Enrollment clinical study 48 week study period Treatment anticoagulant Past history HIV hepatitis A , B C Inability comply demand study Any ocular surgery study eye within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Usher Syndrome Retinitis Pigmentosa</keyword>
	<keyword>Usher Syndrome associate Retinitis Pigmentosa</keyword>
</DOC>